newsfilter
← Latest News
PR Newswire·

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • On October 13, 2025, Tvardi shares plummeted over 80% following disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 for idiopathic pulmonary fibrosis.
  • The study aimed to assess safety, pharmacokinetics, & exploratory lung function outcomes but concluded it did not meet its goals based on safety data & efficacy results including Forced Vital Capacity (FVC) changes.
  • James (Josh) Wilson, a Senior Partner at the firm, is encouraging investors who suffered significant losses to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss legal rights.
  • The firm offers confidential case discussions & directs investors to www.faruqilaw.com/TVRD for further information on the investigation.
  • This announcement is attorney advertising by Faruqi & Faruqi, LLP, with prior results not guaranteeing future outcomes.